DIRS.INFO The most relevant business & tech news

A few compounds picked by AI are now in development, but those bets will take years to play out. Reuters interviews with more than a dozen pharmaceutical company executives, drug regulators, public health experts and AI firms show, however, that the technology is playing a sizeable and growing role in human drug trials. The U.S. Food and Drug Administration (FDA) said it had received about 300 applications that incorporate AI or machine learning in drug development from 2016 through 2022. Without AI, Bayer said it would have spent millions more, and taken up to nine months longer to recruit volunteers. Finding real-world patients by mining electronic patient data can be done manually, but using AI speeds up the process dramatically.

Persons: Dado Ruvic, Jeffrey Morgan, Amgen, Badhri Srinivasan, Sameer Pujari, drugmaker Bayer, Bayer, Blythe Adamson, Roche, Richard Pazdur, Gen Li, John Concato, Natalie Grover, Martin Coulter, Julie Steenhuysen, Josephine Mason, David Clarke Organizations: Pharmaceutical Research, REUTERS, Pharmaceutical, Bayer, Novartis, Deloitte, U.S . Food, Drug Administration, Reuters, World Health, Flatiron Health, FDA, European Medicines Agency, FDA's Oncology, Excellence, Medical, FDA's Center, Drug, Research, Thomson Locations: U.S, Johannesburg, Texas, Finland, United States, London, Chicago

REUTERS/Amit Dave/File PhotoNEW DELHI, July 8 (Reuters) - An Indian court rejected PepsiCo Inc's appeal against an order that revoked a patent for a potato variety grown exclusively for the New York-based company's popular Lay's potato chips. The authority removed PepsiCo's patent cover after Kavitha Kuruganti, a farmers' rights activist, argued that the company cannot claim a patent over a seed variety. PepsiCo petitioned the Delhi High Court against the revocation of the patent cover. In its order dated July 5, Delhi High Court judge Navin Chawla dismissed PepsiCo's appeal against the authority's decision. In 2019, PepsiCo sued some Indian farmers for cultivating the FC5 potato variety, accusing growers of infringing its patent.

Persons: Amit Dave, Kavitha Kuruganti, Navin Chawla, Kuruganti, Mayank Bhardwaj, Sumit Khanna, Kim Coghill Organizations: REUTERS, PepsiCo, New, ' Rights, Authority, Court, Monsanto, drugmaker Bayer AG, Thomson Locations: Ahmedabad, India, DELHI, New York, Delhi, PepsiCo India, U.S

REUTERS/Tom KaeckenhoffLEVERKUSEN, Germany, April 5 (Reuters) - Incoming Bayer (BAYGn.DE) chief executive Bill Anderson says he is keeping an open mind on whether to break up the company into smaller pieces, as some fidgety investors want. "That's why I said I am going to have an open mind," he said. On the stock market Bayer, once the most valuable company on Germany's DAX blue-chip index, is now worth only about the same as it paid for Monsanto. At Bayer, he said he did not have his own desk and made use of the company's meeting rooms as needed. Professing a love of American football, hiking and snowboarding, he was also effusive about Bayer as a company and its heritage of medicines such as Aspirin.

☆ U.S. FDA to restrict unlawful import of veterinary tranquilizer Xylazine
▼ + stars: | 2023-02-28 | by ( ) www.reuters.com time to read: +1 min

Feb 28 (Reuters) - U.S. health regulators on Tuesday issued an import alert for drug ingredients and products related to Xylazine, used largely as a veterinary tranquilizer but has been a drug of abuse, to restrict its unlawful entry into the United States. The Food and Drug Administration (FDA) said its move aims to prevent the drug from entering the U.S. market for illicit purposes, while maintaining availability for its legitimate uses in animals. Under the alert, the FDA will do an entry review of evidence offered by importers if incoming Xylazine is properly labeled, not adulterated, and for legitimate use. Xylazine is approved by the FDA only for veterinary use and German drugmaker Bayer's (BAYGn.DE) animal sedative drug Rompun is among the drugs which are based on Xylazine. "The FDA remains concerned about the increasing prevalence of Xylazine mixed with illicit drugs, and this action is one part of broader efforts the agency is undertaking to address this issue," FDA Commissioner Robert Califf said in the statement.

☆ Big Pharma’s heartburn win is a valuation salve
▼ + stars: | 2022-12-07 | by ( Aimee Donnellan | ) www.reuters.com time to read: +3 min

The equity value of GSK (GSK.L), Sanofi (SASY.PA) and Haleon (HLN.L) crashed in August, after analysts warned of a massive thwack linked to claims that heartburn medication Zantac caused cancer. On Tuesday, a Florida judge broadly agreed and threw out roughly 50,000 claims in federal court. Morgan Stanley analysts had estimated the overall Zantac litigation hit could have been as high as $45 billion. The Zantac judge has just proved that courts can be a help as well as a hindrance. Shares in GSK were up 9% to 15.08 pounds as of 0958 GMT on Dec. 7, while Sanofi rose 5% to 90.03 euros.

Search resuls for: "drugmaker Bayer"

5 mentions found